BofA analyst Tim Anderson notes Pfizer (PFE) announced danuglipron, an oral GLP-1 obesity, is being discontinued, following a case of liver injury seen in the phase 1 study. The firm points out ...

BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ETCompany ParticipantsJohn Reed - Executive Vice ...

Thanks for joining us. I'm Tim Anderson, the U.S. Pharma and Biotech analyst at Bank of America. Happy to have Lilly here on this final day of the conference. We have Lucas Montarce, who's ...

Thanks for joining us. I’m Tim Anderson, the U.S. large cap pharma and biotech analyst of Bank of America and excited to have Gilead with us today, specifically Johanna Mercier, who serves as ...

BofA Securities analyst Tim Anderson sees promise for a handful of large-cap competitors. In a note Wednesday, he said the ...

Citing the Mountain View, California-based firm’s latest 10-K filed last month without a press release or management commentary, BofA analyst Tim Anderson pointed out that IGMS recorded $183.8M ...

In the video above, BofA Securities senior pharma & biotech analyst Tim Anderson describes how tariffs will impact the pharmaceutical stocks he covers. He also explains why Eli Lilly (LLY ...

BofA Securities analyst Tim Anderson writes, “Arguably one of the biggest, most important, most closely-watched pipeline events in large cap biopharma has just played out. And it was favorable.” ...